With one of the largest footprints in biotech, Cowen sets the standard for thought leadership and impactful strategic advice.

Research capabilities for
Biotech sector

Cowen’s biotech team has one of the largest research footprints in the space, covering companies pioneering the treatment of diseases. Our analysts’ work has been validated in third-party polls, such as Institutional Investor’s All-America Research Team, the Greenwich Associates poll, and Starmine. In addition to company-specific research, publications such as Biotechnology Quarterly have become legend among investors. Similarly, our Ahead Of The Curve™ reports are at the center of conversation.

Numerous biotechnology reports make use of Cowen’s extensive network of clinicians to help our analysts guage market potential for therapeutics options. We have also created proprietary programs as needed to support our analysts’ research.

Our annual Health Care Conference remains one of Wall Street’s most highly regarded, and is the epicenter of discussion for corporate executives, institutional investors, venture capitalists, and health care professionals. We also host annually the Cowen Therapeutics Conference that provides an ideal forum for objective, first-hand views on both marketed and emerging therapeutics.

Learn more about our research expertise


General Contact

Robert Fagin
Head of Research
D 646 562 1310

Stephen E. Reilly
Co-director of Research
D 617 946 3901

Lisa Thomas
Associate Director of Research
D 646 562 1388

Investment Banking capabilities for
Biotech sector

Cowen is a leading bank for high quality financings and financial advisory for life sciences companies. The biotech investment banking team combines the global resources and full service product capabilities of a leading financial institution with the focus and commitment of a specialty investment banking firm.

We have proven track record of providing impactful strategic advice and a superior ability to execute debt and equity transactions as well mergers and acquisitions. We understand our clients’ unique challenges and opportunities and deliver the entire organization to help clients’ achieve their goals.

Learn more about our investment banking expertise

Latest Transactions

  • Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive, scalable DNA synthesis platform targeted at diverse end markets. The core of Twists platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA
  • Guardant Health, Inc. is a leading molecular diagnostics company focused on enabling precision medicine through use of its proprietary blood-based assays, focused in the emerging liquid biopsy arena. The Companys core Health Oncology Platform is designed to improve patient clinical outcomes, lower healthcare costs, and accelerate biopharmaceutical drug development to manage cancer across all stages of the disease.
  • NGM Bio is a clinical-stage biopharmaceutical company with a drug discovery approach that is currently focused on key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases


General Contact

George Milstein
Head of Health Care
D 415 646 7394